Alliance Formed to Digitalize Medicine and Healthcare
|
By LabMedica International staff writers Posted on 28 Jun 2017 |

Image: A new alliance has been formed with the goal of driving digitization in medicine and healthcare (Photo courtesy of PixelsTech).
The Universitätsklinikum Erlangen, Siemens Healthineers (Erlangen, Germany), the Friedrich-Alexander-Universität-Erlangen-Nürnberg (FAU), the Fraunhofer Institute for Integrated Circuits (IIS), and Medical Valley EMN have entered into an alliance to establish the Digital Health Innovation Platform (d.hip) with the aim of driving digitalization in medicine and healthcare.
Founded in 1815, the Universitätsklinikum Erlangen covers all the areas of modern medicine with its 24 departments, 19 independent departments, and 7 institutes, and uses the latest knowledge from medical research and state-of-the-art equipment. The FAU, founded in 1743, is one of the largest universities in Germany, with around 40,000 students, 263 degree programs, 4,000 academic staff in the sciences (including 576 professors), about 180 million euros (2016) in third-party funding, and 500 partnerships with universities around the world.
The Fraunhofer IIS is one of the world's leading application-oriented research institutions for microelectronic and IT system solutions and services. In close cooperation with partners and clients, it provides R&D services in various areas, including imaging systems and medical technology, among others. Medical Valley EMN e.V. has been operating as a cluster management organization since 2007 and currently comprises 190 members from the areas of business, academia, healthcare, networks, and politics. It undertakes a variety of functions, including the coordination of the “Digital Medicine/Health” platform as part of the Zentrum Digitalisierung Bayern (Bavarian Center for Digitalization), coordination of the “model region for digital healthcare management in Franconia” research initiative, and management of the “Digital Health Hub” as part of an initiative by the Federal Ministry for Economic Affairs. Siemens Healthineers, the separately managed healthcare business of Siemens AG, offers a comprehensive portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine.
The partners will be combining their medical, technical, and economical expertise to stimulate research into new areas and to conduct development so that it is even more interdisciplinary, clinically and scientifically relevant, and practice-oriented than ever. The platform will make it possible to implement innovations more efficiently and effectively, thereby reducing the time-to-market. The partners will also use their combined expertise to generate innovations. Among other things, machine learning will be used to render hospital procedures more efficient. For example, automated processes in clinical imaging can be tested that permit earlier diagnoses of breast cancer with a better detection rate. Methods for mathematical optimization and machine learning can help optimize the planning of operations, thus improving planning reliability.
Additionally, the partners see the integration of new technologies as having tremendous potential for improving medical care. “Clinical-grade wearables and sensor-based monitoring can promote a healthier lifestyle and improve treatment compliance or help to introduce adjustments to treatment early on. Intelligent image analysis methods for digital pathology can also support the selection and adjustment of individual treatments for tumor patients,” said Prof. Dr. Albert Heuberger, Director of the Fraunhofer Institute for Integrated Circuits IIS in Erlangen.
“Siemens Healthineers has committed itself to helping healthcare providers to overcome their current challenges and to continue their development in their particular business environment,” said Dr. Arthur Kaindl, General Manager of Digital Health Services, Siemens Healthineers. “We will contribute to d.hip our extensive expertise in the area of medical and laboratory technology and we want to make sure that our customers can use innovations in the field of digitalization as early as possible to improve medical patient care and reduce healthcare costs.”
Founded in 1815, the Universitätsklinikum Erlangen covers all the areas of modern medicine with its 24 departments, 19 independent departments, and 7 institutes, and uses the latest knowledge from medical research and state-of-the-art equipment. The FAU, founded in 1743, is one of the largest universities in Germany, with around 40,000 students, 263 degree programs, 4,000 academic staff in the sciences (including 576 professors), about 180 million euros (2016) in third-party funding, and 500 partnerships with universities around the world.
The Fraunhofer IIS is one of the world's leading application-oriented research institutions for microelectronic and IT system solutions and services. In close cooperation with partners and clients, it provides R&D services in various areas, including imaging systems and medical technology, among others. Medical Valley EMN e.V. has been operating as a cluster management organization since 2007 and currently comprises 190 members from the areas of business, academia, healthcare, networks, and politics. It undertakes a variety of functions, including the coordination of the “Digital Medicine/Health” platform as part of the Zentrum Digitalisierung Bayern (Bavarian Center for Digitalization), coordination of the “model region for digital healthcare management in Franconia” research initiative, and management of the “Digital Health Hub” as part of an initiative by the Federal Ministry for Economic Affairs. Siemens Healthineers, the separately managed healthcare business of Siemens AG, offers a comprehensive portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine.
The partners will be combining their medical, technical, and economical expertise to stimulate research into new areas and to conduct development so that it is even more interdisciplinary, clinically and scientifically relevant, and practice-oriented than ever. The platform will make it possible to implement innovations more efficiently and effectively, thereby reducing the time-to-market. The partners will also use their combined expertise to generate innovations. Among other things, machine learning will be used to render hospital procedures more efficient. For example, automated processes in clinical imaging can be tested that permit earlier diagnoses of breast cancer with a better detection rate. Methods for mathematical optimization and machine learning can help optimize the planning of operations, thus improving planning reliability.
Additionally, the partners see the integration of new technologies as having tremendous potential for improving medical care. “Clinical-grade wearables and sensor-based monitoring can promote a healthier lifestyle and improve treatment compliance or help to introduce adjustments to treatment early on. Intelligent image analysis methods for digital pathology can also support the selection and adjustment of individual treatments for tumor patients,” said Prof. Dr. Albert Heuberger, Director of the Fraunhofer Institute for Integrated Circuits IIS in Erlangen.
“Siemens Healthineers has committed itself to helping healthcare providers to overcome their current challenges and to continue their development in their particular business environment,” said Dr. Arthur Kaindl, General Manager of Digital Health Services, Siemens Healthineers. “We will contribute to d.hip our extensive expertise in the area of medical and laboratory technology and we want to make sure that our customers can use innovations in the field of digitalization as early as possible to improve medical patient care and reduce healthcare costs.”
Latest Industry News
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more







